Latest News

The study is assessing the safety and preliminary efficacy of CD28 co-stimulation in patients with mCRPC.

Andrew Peterson, MD, discusses the quality-of-life impact of post-cancer incontinence and advances in electronically controlled artificial urinary sphincters.

Eugene Cone, MD, discusses the impact of ongoing BCG supply challenges and the potential role of alternative and recombinant strains for NMIBC care.

Independent urology faces stagnant Medicare pay, rising costs, prior auth burden, and consolidation pressure, Celeste Kirschner, CAE, MHSA, says.

In this episode, Karen Bigman, MBA, joins to discuss sexual health, intimacy, and relationship challenges facing adults as they navigate midlife and beyond.

Lorelei A. Mucci, ScD, MPH, discusses the evolving evidence surrounding diet, physical activity, and other lifestyle factors in prostate cancer care.

Urologists compare ADT plus ARPI doublets and docetaxel triplets in mCSPC, weighing efficacy, safety, cognition, and cost against patient goals.

All patients have been treated in the phase 3 ENLIGHTED trial, evaluating padeliporfin VTP for low-grade upper tract urothelial carcinoma.

Martin Schoen, MD, PhD, explains how real-world evidence can help compare ARPIs and why study design and patient selection are critical to interpretation.

A randomized trial will test whether an app-guided, at-home PSA screening approach can improve prostate cancer screening among Black men.

Dabogratinib showed early activity and manageable safety in FGFR3-altered LG-IR-NMIBC, supporting advancement to a planned registrational study in the adjuvant setting.

Advocacy through groups like BCAN and the AUA shapes urologic oncology policy—driving funding, screening access, and equity in cancer care, the authors write.

The Zenflow Spring Implant and Delivery System has entered commercial use for BPH following its FDA approval in December 2025.